bupropion hydrochloride; dextromethorphan hydrobromide - Profile
What are the generic drug sources for bupropion hydrochloride; dextromethorphan hydrobromide and what is the scope of patent protection?
Bupropion hydrochloride; dextromethorphan hydrobromide
is the generic ingredient in one branded drug marketed by Axsome and is included in one NDA. There are one hundred and forty-eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.Summary for bupropion hydrochloride; dextromethorphan hydrobromide
| International Patents: | 269 |
| US Patents: | 145 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for bupropion hydrochloride; dextromethorphan hydrobromide |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for bupropion hydrochloride; dextromethorphan hydrobromide
Generic Entry Date for bupropion hydrochloride; dextromethorphan hydrobromide*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET, EXTENDED RELEASE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Paragraph IV (Patent) Challenges for BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| AUVELITY | Extended-release Tablet | bupropion hydrochloride; dextromethorphan hydrobromide | 45 mg/105 mg | 215430 | 1 | 2022-12-22 |
US Patents and Regulatory Information for bupropion hydrochloride; dextromethorphan hydrobromide
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Axsome | AUVELITY | bupropion hydrochloride; dextromethorphan hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 215430-002 | Apr 30, 2026 | RX | Yes | No | 9,968,568 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Axsome | AUVELITY | bupropion hydrochloride; dextromethorphan hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 215430-002 | Apr 30, 2026 | RX | Yes | No | 9,168,234 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Axsome | AUVELITY | bupropion hydrochloride; dextromethorphan hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 215430-002 | Apr 30, 2026 | RX | Yes | No | 10,080,727 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Axsome | AUVELITY | bupropion hydrochloride; dextromethorphan hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 215430-002 | Apr 30, 2026 | RX | Yes | No | 11,590,124 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Axsome | AUVELITY | bupropion hydrochloride; dextromethorphan hydrobromide | TABLET, EXTENDED RELEASE;ORAL | 215430-002 | Apr 30, 2026 | RX | Yes | No | 11,291,638 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for bupropion hydrochloride; dextromethorphan hydrobromide
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2014346807 | ⤷ Start Trial | |
| Australia | 2015350559 | ⤷ Start Trial | |
| Australia | 2018203638 | ⤷ Start Trial | |
| Australia | 2019201548 | ⤷ Start Trial | |
| Australia | 2019223187 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for bupropion hydrochloride; dextromethorphan hydrobromide
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2316456 | CR 2017 00062 | Denmark | ⤷ Start Trial | PRODUCT NAME: NALTREXON ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER NALTREXONHYDROCHLORID, OG BUPROPION ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER BUPROPIONHYDROCHLORID; REG. NO/DATE: EU/1/14/988 20150330 |
| 2316456 | 300918 | Netherlands | ⤷ Start Trial | PRODUCT NAME: NALTREXON OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER NALTREXONHYDROCHLORIDE, EN BUPROPION OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER BUPROPIONHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/14/988 20150330 |
| 0467488 | SPC/GB00/019 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: BUPROPION HYDROCHLORIDE; REGISTERED: NL RVG 24160 19991201; UK PL 10949/0340 20000607 |
| 2316456 | 1790064-8 | Sweden | ⤷ Start Trial | PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE; REG. NO/DATE: EU/1/14/988 20150330 |
| 2316456 | 349 22-2017 | Slovakia | ⤷ Start Trial | PRODUCT NAME: KOMBINACIA NALTREXONU VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM A BUPROPIONU VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/14/988 20150330 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Investment Scenario, Market Dynamics, and Financial Trajectory for Bupropion Hydrochloride and Dextromethorphan Hydrobromide
More… ↓
